Mirae Asset Global ETFs Holdings’s Celldex Therapeutics CLDX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58M	Buy	42,518 +7,179	+20%	+$232K	﹤0.01%	1379
2026 Q1	$1.11M	Sell	35,339 -1,727	-5%	-$47.1K	﹤0.01%	1471
2025 Q4	$1M	Buy	37,066 +1,653	+5%	+$43.5K	﹤0.01%	1517
2025 Q3	$918K	Sell	35,413 -3,975	-10%	-$92.1K	﹤0.01%	1539
2025 Q2	$801K	Sell	39,388 -4,063	-9%	-$79.1K	﹤0.01%	1554
2025 Q1	$798K	Buy	43,451 +680	+2%	+$15.2K	﹤0.01%	1606
2024 Q4	$1.08M	Buy	42,771 +3,830	+10%	+$104K	﹤0.01%	1503
2024 Q3	$1.32M	Buy	38,941 +3,529	+10%	+$134K	﹤0.01%	1382
2024 Q2	$1.31M	Buy	+35,412	New	+$1.34M	﹤0.01%	1308

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CLDX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Celldex Therapeutics (CLDX) stake by 20% in Q2 2026, buying an estimated $232K and bringing the position to 42,518 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1379.

Mirae Asset Global ETFs Holdings first reported a position in CLDX in Q2 2024 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 42,518 shares of Celldex Therapeutics worth $1.58M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 7,179 Celldex Therapeutics shares in Q2 2026, an estimated $232K.
Celldex Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1379 holding.
Mirae Asset Global ETFs Holdings first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 9 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.